Resilienza e strategie di coping adottate per fronteggiare la pandemia da SARS-CoV-2. Valutazione in una coorte di pazienti con malattie rare scheletriche

Title

Code

Strategie RARE

Type

Osservazionale

Start Year

2021

Status

Terminato

Principal Investigator

051-6366519, 051-6366681

luca.sangiorgi@ior.it

Sangiorgi Luca, MD

Director

Rare skeletal disorders

Operational unit that carry out the study

complex unit

Malattie rare scheletriche

Director

Sangiorgi Luca, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. strategie RARE

Wednesday 10 August 2022, 16:51

PG0005471_2021_strategie RARE.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Resilienza e strategie di coping adottate per fronteggiare la pandemia da SARS-CoV-2. Valutazione in una coorte di pazienti con malattie rare scheletriche

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Resilienza e strategie di coping adottate per fronteggiare la pandemia da SARS-CoV-2. Valutazione in una coorte di pazienti con malattie rare scheletriche

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in